Nitrous Oxide

證據等級: L5

預測適應症: 1 個

Nitrous Oxide: From Procedural Analgesia to Benign Prostatic Hyperplasia

One-Sentence Summary

Nitrous oxide (N₂O, “laughing gas”) is a well-established inhaled anesthetic and analgesic agent widely used for procedural sedation and pain management. The TxGNN model predicts it may be effective for Benign Prostatic Hyperplasia (BPH), with a prediction score of 99.52%. However, the supporting evidence is critically weak — 1 clinical trial found is about procedural sedation during prostate biopsy (not BPH treatment), and 3 publications all relate to anesthesia in urological settings rather than BPH pharmacotherapy. This prediction is assessed as model artifact rather than a genuine therapeutic signal.

Quick Overview

Item	Content
Original Indication	Inhaled procedural analgesia/anesthesia (no formal Philippines registration)
Predicted New Indication	Benign Prostatic Hyperplasia (BPH)
TxGNN Prediction Score	99.52%
Evidence Level	L5 — Model prediction only; no supporting therapeutic studies
Philippines Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacology, nitrous oxide acts primarily on NMDA receptors and opioid receptors, producing analgesia and anxiolysis via inhalational delivery. It has no established pharmacological target relevant to BPH pathophysiology.

BPH is treated via two main mechanisms: α₁-adrenergic receptor blockade (e.g., tamsulosin), which relaxes prostatic smooth muscle tone, or 5α-reductase inhibition (e.g., finasteride), which reduces dihydrotestosterone (DHT)-driven prostate volume growth. Nitrous oxide has no known activity on either pathway, and does not affect prostatic smooth muscle tension, prostate volume, or DHT synthesis.

A critical confound must be flagged: the TxGNN model may be conflating Nitrous oxide (N₂O, laughing gas) with Nitric oxide (NO, nitrogen monoxide). Nitric oxide — an entirely distinct compound — does have smooth muscle relaxation effects relevant to lower urinary tract physiology and has been studied in BPH contexts. The high TxGNN score (0.9952) most likely reflects a co-occurrence bias in training data, where N₂O appears frequently alongside urological procedures (e.g., prostate biopsies), rather than any true disease-modifying relationship with BPH. This prediction is not considered mechanistically plausible.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05803096	Phase 4	Completed	143	Self-administered N₂O during transrectal prostate biopsy to reduce anxiety and pain — procedural sedation only, no BPH treatment endpoints

⚠️ Note: The only identified trial evaluates N₂O as an anxiolytic/analgesic adjunct during prostate biopsy, not as a treatment for BPH. No endpoints relevant to BPH (IPSS score, urinary flow rate, prostate volume, PSA) were studied. This trial provides zero evidence for N₂O as a BPH therapy.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
4171323	1968	Technical Report	International Surgery	Equipment description for cryotherapy of prostate obstruction — N₂O used as cryogen, not pharmacotherapy
4108916	1971	Case Series	Zeitschrift für Anasthesie	Combination anesthesia with methohexital in high-risk urological patients — anesthetic management, not BPH treatment
9223887	1997	Case Report	Masui (Japanese Journal of Anesthesiology)	Anesthetic management for suprapubic prostatectomy in a patient with pure autonomic failure — anesthesia context only

⚠️ Note: All three publications address anesthetic or procedural use of N₂O in urological settings. None study N₂O as a therapeutic agent for BPH. These publications do not constitute evidence for drug repurposing.

Philippines Market Information

Nitrous oxide has no registered pharmaceutical products in the Philippines (FDA Philippines). No authorization records are available.

Safety Considerations

Please refer to the package insert for safety information. No Philippines-specific label warnings, contraindications, or drug interaction data were available in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is high (99.52%), but all available evidence indicates this is a model artifact driven by co-occurrence bias — N₂O co-appears with prostate-related procedures in training data without any pharmacological relevance to BPH. There is no mechanistic plausibility, no BPH-directed clinical trial evidence, and no supporting literature. Additionally, the model may be conflating nitrous oxide (N₂O) with nitric oxide (NO), which are chemically and pharmacologically distinct compounds.

To proceed, the following would be needed:

Clarification of whether TxGNN’s prediction is indeed for N₂O (DB06690) versus NO — review the knowledge graph node assignment
A mechanistic hypothesis explaining how NMDA receptor antagonism or opioid receptor modulation could improve BPH symptoms or progression
At minimum one preclinical study (in vitro or animal model) demonstrating N₂O activity on prostatic smooth muscle, 5α-reductase, or relevant lower urinary tract biomarkers
Given the absence of Philippines registration, regulatory pathway assessment would also be required before any clinical development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.